Methods of administering dantrolene for the acute treatment of cardiac arrhythmias
AssigneeUniversity Health Network, Toronto General Hospita
InventorKumaraswamy Nanthakumar
Life of this patent
Estimating the term…
Abstract
The present description relates to methods of administering effective amounts of an anti-arrhythmic agent, e.g., dantrolene, azumolene or a pharmaceutically acceptable salt thereof, for the acute treatment of cardiac arrhythmias, e.g., atrial fibrillation, premature ventricular contraction, ventricular tachycardia or ventricular fibrillation, and prevention of subsequent cardiac arrhythmias, wherein the methods effectuate a reduction in morbidity and mortality.
Claims17
-10. (canceled)
A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of dantrolene, azumolene, a dantrolene derivative, analog, pharmaceutically acceptable salt thereof or a combination thereof approximately during or following cardiac arrest, wherein the method is effective in treating or preventing cardiac arrest, cardiac arrhythmia, premature ventricular contraction (PVC) induced left ventricular dysfunction, atrial fibrillation induced left ventricular dysfunction, ventricular arrhythmia, and a combination thereof.
A method for acute treatment of cardiac arrest comprising:
- (i) performing CPR or defibrillation or both on a subject in need thereof;
- (ii) administering a therapeutically effective amount of at least one of dantrolene sodium, azumolene or a combination thereof to the subject approximately contemporaneously with or subsequent to performing step (i), wherein the method is effective for abrogating or ameliorating a detrimental effect of cardiac arrest.
A method for the treatment of premature ventricular contraction (PVC) induced left ventricle (VA) dysfunction in a subject in need thereof comprising administering a therapeutically effective amount of at least one of dantrolene sodium, azumolene or a combination thereof to the subject approximately during or following a PVC event, wherein the method is effective in treating or preventing PVC induced LV dysfunction.
A method for the treatment of atrial fibrillation (AF) induced left ventricle (LV) dysfunction in a subject in need thereof comprising administering a therapeutically effective amount of at least one of dantrolene sodium, azumolene or a combination thereof to the subject approximately during or following AF, wherein the method is effective in treating or preventing AF induced LV dysfunction.
Dependencies are inferred from the claim text.